JP2015512418A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015512418A5 JP2015512418A5 JP2015503627A JP2015503627A JP2015512418A5 JP 2015512418 A5 JP2015512418 A5 JP 2015512418A5 JP 2015503627 A JP2015503627 A JP 2015503627A JP 2015503627 A JP2015503627 A JP 2015503627A JP 2015512418 A5 JP2015512418 A5 JP 2015512418A5
- Authority
- JP
- Japan
- Prior art keywords
- scopolamine
- ketamine
- disorder
- medicament according
- human subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 claims description 42
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims description 42
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims description 42
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims description 42
- 229960003299 ketamine Drugs 0.000 claims description 42
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims description 42
- 229960002646 scopolamine Drugs 0.000 claims description 42
- 230000037396 body weight Effects 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 5
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 208000020401 Depressive disease Diseases 0.000 claims description 4
- 208000019022 Mood disease Diseases 0.000 claims description 4
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 208000024732 dysthymic disease Diseases 0.000 claims description 4
- 208000024714 major depressive disease Diseases 0.000 claims description 4
- 208000019906 panic disease Diseases 0.000 claims description 4
- 206010033675 panniculitis Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 4
- 208000012672 seasonal affective disease Diseases 0.000 claims description 4
- 210000004304 subcutaneous tissue Anatomy 0.000 claims description 4
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims 20
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 21
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 241000282412 Homo Species 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261618212P | 2012-03-30 | 2012-03-30 | |
| US61/618,212 | 2012-03-30 | ||
| PCT/US2013/034524 WO2013149102A1 (en) | 2012-03-30 | 2013-03-29 | Compositions comprising scopolamine and ketamine in the treatment of depression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018136350A Division JP2018184440A (ja) | 2012-03-30 | 2018-07-20 | うつ病の治療におけるスコポラミンおよびケタミンを含む組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015512418A JP2015512418A (ja) | 2015-04-27 |
| JP2015512418A5 true JP2015512418A5 (enExample) | 2015-06-11 |
Family
ID=49261273
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015503627A Pending JP2015512418A (ja) | 2012-03-30 | 2013-03-29 | うつ病の治療におけるスコポラミンおよびケタミンを含む組成物 |
| JP2018136350A Pending JP2018184440A (ja) | 2012-03-30 | 2018-07-20 | うつ病の治療におけるスコポラミンおよびケタミンを含む組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018136350A Pending JP2018184440A (ja) | 2012-03-30 | 2018-07-20 | うつ病の治療におけるスコポラミンおよびケタミンを含む組成物 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20150057306A1 (enExample) |
| EP (1) | EP2830604A4 (enExample) |
| JP (2) | JP2015512418A (enExample) |
| WO (1) | WO2013149102A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140274981A1 (en) | 2013-03-15 | 2014-09-18 | Janssen Pharmaceutica Nv | Pharmaceutical composition of s-ketamine hydrochloride |
| CA2961208A1 (en) | 2014-09-15 | 2016-03-24 | Janssen Pharmaceutica Nv | Val66met (snp rs6265) genotype specific dosing regimens and methods for the treatment of depression |
| US20160338977A1 (en) * | 2015-05-20 | 2016-11-24 | Janssen Pharmaceutica Nv | Methods and kits for treating depression |
| KR102299359B1 (ko) | 2015-06-27 | 2021-09-07 | 쉐녹스 파마슈티컬스, 엘엘씨 | 케타민 경피 전달 시스템 |
| EP3377050A4 (en) | 2015-11-17 | 2019-11-20 | The Trustees of Columbia University in the City of New York | PHARMACOLOGICAL PROPHYLACTICS AGAINST STRESS-INDUCED AFFECTIVE DISORDERS AND THEIR ASSOCIATED SYMPTOMS |
| US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
| US12090123B2 (en) | 2017-10-10 | 2024-09-17 | Douglas Pharmaceuticals Ltd. | Extended release pharmaceutical formulation |
| US10441544B2 (en) | 2017-10-10 | 2019-10-15 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation |
| US10869838B2 (en) | 2017-10-10 | 2020-12-22 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation |
| CA3077645A1 (en) | 2017-10-10 | 2019-04-18 | Douglas Pharmaceuticals Ltd. | A solid extended-release pharmaceutical formulations comprising ketamine or norketamine |
| US11471415B2 (en) | 2017-10-10 | 2022-10-18 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation and methods of treatment |
| WO2019094757A1 (en) | 2017-11-09 | 2019-05-16 | The Trustees Of Columbia University In The City Of New York | Pharmacological prophylactics against stress-induced affective disorders in females |
| US11622948B2 (en) | 2017-11-09 | 2023-04-11 | The Trustees Of Columbia University In The City Of New York | Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders |
| WO2019099568A1 (en) * | 2017-11-14 | 2019-05-23 | Bexson Biomedical, Inc. | Systems, devices, formulations and methods for controlled drug delivery |
| CN112423789A (zh) | 2017-12-22 | 2021-02-26 | 詹森药业有限公司 | 用于治疗抑郁症的艾司氯胺酮 |
| HUE058320T2 (hu) | 2017-12-29 | 2022-07-28 | Celon Pharma Sa | Száraz por alakú ketamin készítmény pulmonáris adagolásra kezelésnek ellenálló depresszió esetén |
| JP7548669B2 (ja) | 2018-02-15 | 2024-09-10 | 国立大学法人千葉大学 | 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物 |
| TWI767133B (zh) * | 2018-08-02 | 2022-06-11 | 台灣微脂體股份有限公司 | 含有治療憂鬱症或焦慮症之治療劑的緩釋組合物及其用途 |
| IL318198A (en) | 2019-03-05 | 2025-03-01 | Janssen Pharmaceuticals Inc | Esketamine for the treatment of depression |
| JP2022533971A (ja) * | 2019-05-15 | 2022-07-27 | ベクソン バイオメディカル，インク． | 皮下注射のためのケタミン製剤 |
| EP4041209A4 (en) | 2019-10-11 | 2024-01-24 | Pike Therapeutics, Inc. | TRANSDERMAL COMPOSITIONS COMPRISING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF EPILEPTIC DISORDERS |
| WO2022011170A1 (en) * | 2020-07-09 | 2022-01-13 | Light Aqua Llc | Compositions and methods for treating mood disorders and circadian rhythm sleep disorders |
| EP4247340A4 (en) | 2020-11-18 | 2024-10-02 | Bexson Biomedical, Inc. | COMPLEXING SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS |
| KR20230121776A (ko) * | 2020-12-16 | 2023-08-21 | 캄테크, 인크. | 아마니타 무스카리아 화합물 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1060646C (zh) * | 1993-06-07 | 2001-01-17 | 李举寿 | 戒毒注射液及其制造方法 |
| US8859585B2 (en) * | 2005-05-25 | 2014-10-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Scopolamine for the treatment of depression and anxiety |
| EP2012762A4 (en) * | 2006-03-22 | 2010-03-10 | Sinai School Medicine | INTRANASAL ADMINISTRATION OF KETAMINE FOR THE TREATMENT OF DEPRESSION |
-
2013
- 2013-03-29 US US14/388,410 patent/US20150057306A1/en not_active Abandoned
- 2013-03-29 EP EP13767616.9A patent/EP2830604A4/en not_active Withdrawn
- 2013-03-29 WO PCT/US2013/034524 patent/WO2013149102A1/en not_active Ceased
- 2013-03-29 JP JP2015503627A patent/JP2015512418A/ja active Pending
-
2016
- 2016-03-17 US US15/072,970 patent/US20170042878A1/en not_active Abandoned
-
2018
- 2018-07-20 JP JP2018136350A patent/JP2018184440A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015512418A5 (enExample) | ||
| NZ707377A (en) | Combination therapy methods for treating proliferative diseases | |
| EA201590166A8 (ru) | Комбинированная терапия для лечения рассеянного склероза | |
| JP2014528901A5 (enExample) | ||
| RU2018110647A (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
| MX2010005631A (es) | Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades. | |
| NZ630367A (en) | Methods of treatment of pediatric solid tumor | |
| WO2011041478A8 (en) | Hematopoietic stem cells for use in the treatment of a kidney injury | |
| WO2014184576A3 (en) | Delivery of a therapeutic agent to the cerebral cortex by administering a viral vector by convection enhanced diffusion into the white matter of the brain | |
| Gliedt et al. | Narrative review of perioperative acupuncture for clinicians | |
| JP2011518787A5 (enExample) | ||
| EP3476395A4 (en) | COMPOSITION FOR INJECTION THAT CAN BE USED FOR THE TREATMENT OF CARDIAC DISEASES AND CONTAINING FIBROBLASTS, AND METHOD FOR PRODUCING FIBROBLASTS FOR THERAPEUTIC USE | |
| JP2017524721A5 (enExample) | ||
| EA201592058A1 (ru) | Применение ландиолола гидрохлорида в длительном лечении тахиаритмии | |
| JP2017061488A5 (enExample) | ||
| HK1222585A1 (zh) | 用於提供疼痛减轻和麻醉的二氢埃托啡 | |
| MX2010006724A (es) | Regimenes terapeuticos para el tratamiento de desordenes inmunoinflamatorios. | |
| WO2014100679A8 (en) | Stimulation and enhancement of regeneration of tissues | |
| JP2010538054A5 (enExample) | ||
| JP2016504361A5 (enExample) | ||
| JP2015512923A5 (enExample) | ||
| JP2015508052A5 (enExample) | ||
| EA201590825A1 (ru) | Способы контролирования кровяного давления и снижения диспноэ при сердечной недостаточности | |
| CN104667073A (zh) | 治疗神经衰弱的中药 |